Oct 21, 2026, 3:13 PM
Hoechst Pakistan reports lower quarterly profit and EPS for the quarter ended September 30, 2026
Financial ResultBoard-approved unaudited results show quarterly revenue, operating profit, net profit and EPS all declined year on year. The company also disclosed regulatory approvals for exclusive distribution of Dianatal® Obstetric Gel in Pakistan, with commercialization expected in the first half of 2027.
Key Findings
- Quarterly revenue was Rs. 7,790.374 million, down from Rs. 8,284.284 million.
- Quarterly operating profit declined to Rs. 1,094.857 million from Rs. 1,554.965 million.
- Quarterly profit for the period fell to Rs. 614.346 million from Rs. 875.680 million; EPS declined to Rs. 63.70 from Rs. 90.79.
- No cash dividend, bonus shares, rights shares or other entitlement was declared.
- The company obtained approvals to distribute Dianatal® Obstetric Gel in Pakistan; commercialization is expected in the first half of 2027.
Financial Performance
| Metric | PreviousQuarter ended September 30, 2025 | CurrentQuarter ended September 30, 2026 | Change |
|---|---|---|---|
| Revenue from contract with customers - net | 8,284,284 | 7,790,374 | -6% |
| Gross profit | 3,047,371 | 2,952,406 | -3.1% |
| Operating profit | 1,554,965 | 1,094,857 | -29.6% |
| Profit for the period | 875,680 | 614,346 | -29.8% |
| Earnings per share - basic and diluted (Rupees) | 90.79 | 63.70 | -29.8% |
| Finance costs | (18,263) | (52,567) | +187.8% |
| Cash and bank balances | 134,916 | 105,822 | -21.6% |
⚡
Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.